On March 21, 2017, the U.S. FDA made a safety announcement about a link between textured breast implants and a very rare form of cancer: anaplastic large-cell lymphoma. In the announcement, the FDA called the cancer “breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL).

Since then, the ante has been upped. On May 28 of last year, Health Canada suspended the sale of Allergan Biocell breast implants. In July, the U.S. FDA followed suit with a ban, requesting Allergan to recall all Biocell textured implants.

Dr. Turk hasn’t been placing Biocell textured implants, but we’ve had patients inquiring about what’s going on. To answer that, here’s more information on the recall and ban.

The FDA’s recall

The FDA requested that Allergan recall all Biocell textured breast implants and tissue expanders marketed in the U.S. due to risk of breast implant-associated anaplastic large cell lymphoma, a cancer of the immune system. Based on the currently available information, the FDA’s analysis demonstrated that the risk of BIA-ALCL with Allergan Biocell textured implants is approximately 6 times the risk of BIA-ALCL with textured implants from other manufacturers in the U.S. That’s why the FDA instructed Allergan to stop distribution.

The suspension means that Allergan is no longer allowed to sell its Biocell macro-textured implants in the U.S., and all unused implants are to be sent back to the manufacturer. This only applies to Biocell implants, not any other kinds of implants.

The FDA has not made any recommendation for women to remove Biocell implants if they have them, as the number of cases is exceedingly low. Still, women who have received Allergan Biocell macro-textured implants should be on the lookout for any signs such as swelling, lumps, and pain in the breast.

What is ALCL?

ALCL is an uncommon cancer that can develop in any part of the body, most commonly the lymph nodes and skin. Research suggests that BIA-ALCL is usually found near the breast implant within the surrounding scar tissue, not in the breast itself. The lifetime risk for developing BIA-ALCL from a textured implant is estimated to be from one in 4,000 to one in 30,000. At this point, the type of implant (silicone or saline) doesn’t seem make a difference. It seems to be the texture of the Biocell implants.

How is BIA-ALCL treated?

This is still a very rare risk. Plus, when BIA-ALCL is caught early it is usually curable. Treatment involved surgical removal of the implants and the scar tissue capsule, as the lymphoma appears almost always to be only in the scar tissue capsule.

Do you have questions about breast implants? Please call us at Naples Cosmetic Surgery, (239) 348-4357, to make an appointment or with any concerns you may have.

CONTACT US

  • This field is for validation purposes and should be left unchanged.
Scroll to Top